With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...

Novartis’ new CEO Vas Narasimhan has shown his priorities by promoting the company’s digital chief to the executive committee. New broom and chief digital officer Bertrand Bodson has been ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. The Swiss group will see major ...

said chief executive Vas Narasimhan. The event comes just over a year after Novartis completed the dismantling of its diversified life sciences model with the spinout of generic and biosimilar ...

Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

As it stands, Sandoz will be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) programme in the US, although Novartis chief executive Vas Narasimhan said this morning he ...

Novartis has been streamlining its business since CEO Vas Narasimhan took over, and has continued that push with the divestment of three drugs to Recordati for $390 million upfront. The Italian ...

“Therefore, I decided to accept a new role as CEO of a US-based biotech. I want to thank [CEO Vas Narasimhan] for the opportunity to work at this great company and to everyone in oncology for ...

Novartis’ new CEO Vas Narasimhan pressed the button on divesting Alcon last June, shortly after taking the helm from predecessor Joe Jimenez, although a spin-out had been out on the table the ...